ADCYAP1 and Kennedy disease: IN administration of a PACAP analog for 3 months (5×/week) can promote polyglutamine-expanded androgen receptor (polyQ-AR) degradation, by decreasing phosphorylation, leading to destabilization, and improve neurotoxicity associated with spinobulbar muscular atrophy (SBMA) [89].